scholarly journals An Exploratory Clinical Trial of a Novel Treatment for Giant Congenital Melanocytic Nevi Combining Inactivated Autologous Nevus Tissue by High Hydrostatic Pressure and a Cultured Epidermal Autograft: Study Protocol

2016 ◽  
Vol 5 (3) ◽  
pp. e162 ◽  
Author(s):  
Naoki Morimoto ◽  
Chizuru Jinno ◽  
Michiharu Sakamoto ◽  
Natsuko Kakudo ◽  
Tetsuji Yamaoka ◽  
...  
2016 ◽  
Vol 201 (3) ◽  
pp. 170-179 ◽  
Author(s):  
Naoki Morimoto ◽  
Chizuru Jinno ◽  
Atsushi Mahara ◽  
Natsuko Kakudo ◽  
Toshia Fujisato ◽  
...  

High hydrostatic pressure (HHP) technology is a physical method for inactivating tissue. We reported that nevus specimens were inactivated after HHP at 200 MPa and that the inactivated nevus could be used as autologous dermis for covering skin defects. In this study, we verified the inactivation of nevus specimens using a newly developed portable HHP device which will be used in a clinical trial. Nevus tissue specimens were obtained from 5 patients (mean age 7.2 years, range 1-19). We cultured fibroblasts and nevus cells from the tissue specimens and then evaluated their inactivation after HHP at 200 MPa by confirming the attachment of the suspensions and by the live/dead staining of the suspensions, through the dissociation of the cells on chamber slides and by the live/dead staining of the remaining cells. The cells were also quantitatively evaluated by WST-8 assay. We then confirmed the inactivation of the nevus specimens after HHP using explant culture. Our results indicated that fibroblasts and nevus cells were inactivated after HHP at 200 MPa, with the exception of a small percentage of green-colored cells, which reflected the remaining activity of the cellular esterases after HHP. No cells migrated from the nevus specimens after HHP at 200 MPa. We verified the inactivation of fibroblasts and nevus cells cultured from nevus specimens, and in the nevus samples themselves after pressurization at 200 MPa using this device. This device could be used in clinical trials for giant congenital melanocytic nevi and may thus become useful in various medical fields.


2018 ◽  
Vol 10 (1) ◽  
pp. 24-28 ◽  
Author(s):  
Girish Gulab Meshram ◽  
Neeraj Kaur ◽  
Kanwaljeet Singh Hura

Giant congenital melanocytic nevi (GCMN) are a rare occurrence. Gain-of-function mutation in the NRAS gene is found to be associated with GCMN, causing abnormal proliferation of embryonic melanoblasts. The two major complications associated with GCMN are malignant melanoma and neurocutaneous melanosis. Treatment of GCMN has conventionally been surgical. However, the role of NRAS inhibitors and inactivation of nevus tissue by high hydrostatic pressure are being explored. We present a case of a 1-day-old neonate born with GCMN, along with a review of the literature.


2020 ◽  
Vol 83 (1) ◽  
pp. 222-224
Author(s):  
Alejandra Tomás-Velázquez ◽  
Juan Carlos López-Gutiérrez ◽  
Carmen Ceballos ◽  
Jorge M. Núñez-Córdoba ◽  
Pedro Redondo

2008 ◽  
Vol 47 (8) ◽  
pp. 824-826 ◽  
Author(s):  
Ahdi Amer ◽  
Howard Fischer

Sign in / Sign up

Export Citation Format

Share Document